VKTX
Viking Therapeutics, Inc. NASDAQ Listed Apr 28, 2015$33.97
-0.85%
vs $34.26
Mkt Cap $4.0B
52w Low $22.96
54.5% of range
52w High $43.15
50d MA $34.27
200d MA $33.78
P/E (TTM)
—
EV/EBITDA
—
P/B
6.0x
Debt/Equity
0.0x
ROE
-56.3%
P/FCF
-13.9x
RSI (14)
40.30
ATR (14)
$1.55
Beta
0.82
50d MA
$34.27
200d MA
$33.78
Avg Volume
2.3M
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
9920 Pacific Heights Boulevard · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | AMC | -1.21 | -1.10 | +9.1% | 33.43 | +0.3% | -1.0% | -4.1% | +2.7% | +1.0% | +1.7% | — |
| Apr 29, 2026 | AMC | -1.01 | -1.37 | -35.6% | 31.33 | -2.7% | -0.5% | -3.8% | +5.9% | -1.4% | +3.1% | — |
| Feb 11, 2026 | AMC | -0.89 | -1.38 | -55.1% | 28.55 | +18.2% | +6.8% | -4.9% | +5.0% | -1.0% | +3.2% | — |
| Oct 22, 2025 | AMC | -0.70 | -0.81 | -15.7% | 31.42 | +12.8% | +8.0% | +1.5% | +4.4% | -2.8% | +0.8% | — |
| Jul 23, 2025 | AMC | -0.44 | -0.58 | -31.8% | 33.40 | -5.7% | +0.3% | +2.7% | -3.5% | -0.9% | +2.4% | — |
| Apr 23, 2025 | AMC | -0.34 | -0.41 | -20.6% | 25.79 | +1.2% | -0.5% | -2.6% | +3.8% | +7.7% | +3.3% | — |
| Feb 5, 2025 | AMC | -0.28 | -0.32 | -14.3% | 33.50 | -7.4% | -6.1% | +3.5% | -7.3% | -0.7% | -2.1% | — |
| Oct 23, 2024 | AMC | -0.24 | -0.22 | +8.3% | 60.39 | +8.9% | +21.2% | +6.6% | -4.5% | -1.6% | -2.2% | — |
| Jul 24, 2024 | AMC | -0.26 | -0.20 | +23.1% | 50.41 | +17.0% | +28.3% | +2.0% | -7.2% | -7.7% | +0.8% | — |
| Apr 24, 2024 | AMC | -0.27 | -0.26 | +3.7% | 65.07 | -3.2% | +5.8% | +7.9% | +1.5% | +5.5% | -4.0% | — |
| Feb 7, 2024 | AMC | -0.25 | -0.25 | +0.0% | 24.48 | +5.2% | +18.0% | +5.8% | +3.8% | -3.6% | +5.3% | — |
| Oct 25, 2023 | AMC | -0.22 | -0.23 | -4.5% | 10.67 | -15.7% | -9.4% | -4.4% | +3.7% | +2.4% | -2.4% | — |
| Jul 26, 2023 | AMC | -0.21 | -0.19 | +9.5% | 14.28 | -4.7% | -4.0% | +5.3% | +0.4% | -2.3% | -1.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 28 | Lake Street | Initiates | Buy | $89 | $31.66 | $31.97 | +1.0% | +1.7% | +1.7% | -4.5% | -6.3% | +0.1% |
| May 27 | Truist | Reiterates | Buy | $83 | $30.80 | $31.30 | +1.6% | +2.8% | +1.7% | +1.7% | -4.5% | -6.3% |
| Apr 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.33 | $30.48 | -2.7% | -0.5% | -3.8% | +5.9% | -1.4% | +3.1% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.33 | $32.34 | +0.0% | +0.7% | -1.2% | +3.2% | +3.2% | -5.1% |
| Nov 12 | Canaccord Genuity | Maintains | Buy → Buy | — | $40.60 | $42.22 | +4.0% | +0.4% | -4.4% | +0.3% | -2.3% | -1.2% |
| Oct 24 | JP Morgan | Maintains | Overweight → Overweight | — | $33.92 | $35.00 | +3.2% | +1.5% | +4.4% | -2.8% | +0.8% | +8.4% |
| Oct 23 | Morgan Stanley | Maintains | Overweight → Overweight | — | $31.42 | $35.44 | +12.8% | +8.0% | +1.5% | +4.4% | -2.8% | +0.8% |
| Sep 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.57 | $25.55 | -0.1% | +0.9% | +1.8% | +4.1% | +1.9% | +6.6% |
| Sep 22 | BTIG | Maintains | Buy → Buy | — | $25.40 | $25.35 | -0.2% | +3.3% | -4.9% | +6.6% | -5.8% | +1.9% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.09 | $26.00 | -38.2% | -42.1% | +5.5% | -0.1% | +1.3% | -0.6% |
| Jul 24 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $33.40 | $31.50 | -5.7% | +0.3% | +2.7% | -3.5% | -0.9% | +2.4% |
| Jul 24 | Citigroup | Maintains | Neutral → Neutral | — | $33.40 | $31.50 | -5.7% | +0.3% | +2.7% | -3.5% | -0.9% | +2.4% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.95 | $27.11 | +0.6% | +0.5% | +4.0% | -5.9% | -0.1% | +0.6% |
| Apr 28 | Truist | Maintains | Buy → Buy | — | $24.99 | $25.11 | +0.5% | +3.8% | +7.7% | +3.3% | -0.9% | +2.6% |
| Apr 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $25.79 | $26.09 | +1.2% | -0.5% | -2.6% | +3.8% | +7.7% | +3.3% |
| Apr 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.79 | $26.09 | +1.2% | -0.5% | -2.6% | +3.8% | +7.7% | +3.3% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.60 | $22.04 | -6.6% | +1.4% | -0.9% | +7.4% | +1.2% | -0.5% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.98 | $28.00 | +0.1% | -5.9% | -0.8% | -1.8% | -5.8% | -1.0% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.96 | $26.26 | -6.1% | -5.2% | +11.4% | +0.6% | +3.9% | -3.4% |
| Feb 7 | Maxim Group | Maintains | Buy → Buy | — | $31.46 | $31.40 | -0.2% | +3.5% | -7.3% | -0.7% | -2.1% | +0.6% |
| Feb 7 | B. Riley Securities | Maintains | Buy → Buy | — | $31.46 | $31.40 | -0.2% | +3.5% | -7.3% | -0.7% | -2.1% | +0.6% |
| Feb 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $33.50 | $31.02 | -7.4% | -6.1% | +3.5% | -7.3% | -0.7% | -2.1% |
| Feb 6 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $33.50 | $31.02 | -7.4% | -6.1% | +3.5% | -7.3% | -0.7% | -2.1% |
| Feb 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.50 | $31.02 | -7.4% | -6.1% | +3.5% | -7.3% | -0.7% | -2.1% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.56 | $32.94 | +1.2% | +0.3% | +0.7% | +3.6% | +2.6% | -1.3% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.60 | $40.00 | -1.5% | -3.2% | -1.1% | -12.7% | +2.7% | -6.6% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.66 | $41.52 | -0.3% | -2.5% | -3.2% | -1.1% | -12.7% | +2.7% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.49 | $44.18 | +6.5% | +1.8% | +0.2% | +0.1% | +0.8% | -3.6% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.70 | $43.09 | -7.7% | -18.0% | +8.4% | +1.8% | +0.2% | +0.1% |
| Nov 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.42 | $53.33 | -0.2% | +2.0% | -2.9% | -2.7% | -2.4% | +1.9% |
| Nov 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.99 | $55.27 | +6.3% | +2.8% | +2.0% | -2.9% | -2.7% | -2.4% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.14 | $63.53 | +0.6% | +2.4% | +1.9% | +4.5% | -0.5% | -8.0% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $60.39 | $65.75 | +8.9% | +21.2% | +6.6% | -4.5% | -1.6% | -2.2% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $66.68 | $67.16 | +0.7% | -6.1% | -0.3% | +5.4% | -0.1% | -0.6% |
| Sep 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $61.93 | $62.69 | +1.2% | +1.9% | -1.3% | -1.1% | +2.7% | -2.1% |
| Sep 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $60.83 | $62.71 | +3.1% | +3.3% | +6.2% | +0.6% | -6.2% | +2.4% |
| Jul 25 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $50.41 | $59.00 | +17.0% | +28.3% | +2.0% | -7.2% | -7.7% | +0.8% |
| Jul 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.41 | $59.00 | +17.0% | +28.3% | +2.0% | -7.2% | -7.7% | +0.8% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.74 | $52.42 | -0.6% | -1.2% | -8.3% | -0.9% | +7.1% | +4.4% |
| Jun 17 | Truist | Maintains | Buy → Buy | — | $52.02 | $51.61 | -0.8% | +0.0% | -2.7% | -0.4% | +4.6% | -1.2% |
| Jun 4 | Maxim Group | Maintains | Buy → Buy | — | $62.27 | $65.00 | +4.4% | -9.7% | +4.7% | -6.6% | +1.8% | +0.7% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.27 | $65.00 | +4.4% | -9.7% | +4.7% | -6.6% | +1.8% | +0.7% |
| May 16 | Raymond James | Upgrade | Outperform → Strong Buy | — | $78.01 | $76.26 | -2.2% | -11.5% | -3.0% | +0.8% | -4.9% | -1.9% |
| May 16 | Truist | Maintains | Buy → Buy | — | $78.01 | $76.26 | -2.2% | -11.5% | -3.0% | +0.8% | -4.9% | -1.9% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.07 | $63.00 | -3.2% | +5.8% | +7.9% | +1.5% | +5.5% | -4.0% |
| Mar 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $80.83 | $82.08 | +1.5% | +3.1% | -1.6% | -3.0% | -2.7% | +1.4% |
| Mar 26 | BTIG | Maintains | Buy → Buy | — | $69.19 | $77.51 | +12.0% | +16.8% | +3.1% | -1.6% | -3.0% | -2.7% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.19 | $77.51 | +12.0% | +16.8% | +3.1% | -1.6% | -3.0% | -2.7% |
| Mar 26 | Oppenheimer | Maintains | Outperform → Outperform | — | $69.19 | $77.51 | +12.0% | +16.8% | +3.1% | -1.6% | -3.0% | -2.7% |
| Mar 15 | Maxim Group | Maintains | Buy → Buy | — | $65.05 | $67.20 | +3.3% | -3.8% | +1.3% | +2.9% | +9.0% | -0.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | Mancini Marianna | Chief Operating Officer | Sell | 18,217 | $33.47 | $610K | 422,760 | -0.96% | +1.73% |
| Jul 29, 2026 | ZANTE GREG | Chief Financial Officer | Sell | 21,217 | $33.47 | $710K | 212,204 | -0.96% | +1.73% |
| Jul 29, 2026 | Lian Brian | President & CEO | Sell | 148,517 | $33.32 | $4.9M | 2,572,441 | -0.96% | +1.73% |
8-K
Viking Therapeutics, Inc. -- 8-K Filing
Viking Therapeutics appointed two new Class II directors and ratified CBIZ CPAs P.C. as its auditor, indicating stable governance and continued financial oversight during the company's drug development operations.
May 26
8-K · 1.02
!! High
Ligand Pharmaceuticals Incorporated -- 8-K 1.02: Material Agreement Terminated
The TR-Beta Program license termination with Valley Blvd effective May 4, 2026 removes a development partnership, though the filing doesn't specify whether this was mutual, breach-based, or regulatory-driven—investors should clarify the reason's impact on the company's pipeline.
Apr 30
8-K
Viking Therapeutics, Inc -- 8-K Filing
Unable to provide analysis: this 8-K contains only signature blocks without disclosed material events, transactions, or financial information necessary for investor guidance.
Feb 11
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 6,152,540 | $216M | Reduced | Dec 2025 |
| 2 | Fmr Llc | 6,024,753 | $196M | Reduced | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 5,012,502 | $163M | New | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 4,464,298 | $145M | New | Mar 2026 |
| 5 | Two Sigma Investments, Lp | 4,432,142 | $144M | Added | Mar 2026 |
| 6 | Raymond James Financial Inc | 2,075,403 | $114M | Added | Mar 2026 |
| 7 | D.e. Shaw & Co | 1,676,713 | $55M | Reduced | Mar 2026 |
| 8 | Jane Street Group, Llc | 1,501,117 | $53M | Added | Dec 2025 |
| 9 | Ubs Group Ag | 1,347,472 | $44M | Added | Mar 2026 |
| 10 | Citadel Advisors Llc | 1,262,221 | $41M | Reduced | Mar 2026 |
| 11 | Susquehanna International Group, Llp | 705,809 | $23M | Reduced | Mar 2026 |
| 12 | Northern Trust Corp | 573,276 | $19M | Added | Mar 2026 |
| 13 | Connor, Clark & Lunn Investment Management Ltd. | 518,796 | $18M | Reduced | Dec 2025 |
| 14 | Principal Financial Group Inc | 513,731 | $18M | — | Dec 2025 |
| 15 | Tang Capital Management Llc | 500,000 | $18M | Reduced | Dec 2025 |
| 16 | Bnp Paribas Financial Markets | 540,499 | $18M | Reduced | Mar 2026 |
| 17 | Bank Of New York Mellon Corp | 454,063 | $15M | Reduced | Mar 2026 |
| 18 | Jpmorgan Chase & Co | 485,703 | $15M | Reduced | Mar 2026 |
| 19 | Clearbridge Investments, Llc | 444,781 | $14M | — | Mar 2026 |
| 20 | Royal Bank Of Canada | 397,968 | $13M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$3.96B
Enterprise Value
$3.15B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.05x
P/B
5.99x
P/S
—
P/FCF
-13.85x
EV/EBITDA
—
Shares Out
112.7M
Financials (TTM)
Revenue
$0
Net Income
-$534.8M
EBITDA
-$534.4M
Free Cash Flow
-$278.7M
Op Cash Flow
-$278.7M
EPS Basic
$-3.19
EPS Diluted
$-4.66
EPS Forward
$-4.40
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$715.7M
Total Liab.
$76.7M
Total Equity
$639.1M
Cash
$705.7M
LT Debt
$0
Book Value/Sh
$5.67
Debt/Equity
0.00x
Current Ratio
9.33
Quick Ratio
9.33
Returns & Growth
ROE
-56.3%
ROA
-50.2%
ROIC
-61.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
-215.8%
Price Returns
2W
-1.5%
1M
-14.3%
3M
+9.4%
6M
+20.5%
12M
-9.6%
Technicals
52W High
$43.15
52W Low
$22.96
50d MA
$34.27
200d MA
$33.78
RSI (14)
40.30
ATR (14)
$1.55
Beta
0.82
Avg Volume
2.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$100.75
High
$107.00
Low
$95.00
Median
$100.50
Data updated apr 27, 2026 7:49am
· Source: financialmodelingprep.com